Vigabatrin/CPP-109 Data to be Presented at College on Problems of Drug Dependence Annual Meeting
CORAL GABLES, Fla., June 9 /PRNewswire-FirstCall/ -- Catalyst
Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today announced that on Tuesday,
June 15th at 5:20pm local time, Charles Gorodetzky, MD, PhD will
deliver a presentation entitled "Vigabatrin for the treatment of
stimulant dependence" at the College on Problems of Drug
Dependence's (CPDD) 72nd Annual Meeting in Scottsdale, Arizona. Dr.
Gorodetzky, Catalyst's Chief Medical Officer, will present an
overview of nonclinical and clinical data obtained from studies of
vigabatrin conducted to date which support its continued
development as a treatment for cocaine and methamphetamine
addiction. Further, the Company reported that the presentation
materials from the conference will be posted on June 15th on the
Company's website, www.catalystpharma.com, under "Events and
Presentations."
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a development-stage
biopharmaceutical company focused on the development and
commercialization of prescription drugs targeting diseases of the
central nervous system with a focus on the treatment of drug
addiction, epilepsy and neuropathic pain. Catalyst has two products
in development, and is currently evaluating the lead product
candidate, CPP-109 (vigabatrin, a GABA aminotransferase inhibitor)
for the treatment of cocaine addiction. CPP-109 has been granted
"Fast Track" status by the U.S. Food & Drug Administration
(FDA) for the treatment of cocaine addiction, which indicates that
the FDA has recognized that CPP-109 is intended for the treatment
of a serious or life-threatening condition for which there is no
effective treatment and which demonstrates the potential to address
an unmet medical need. Catalyst also expects to evaluate CPP-109
for the treatment of other addictions and obsessive-compulsive
disorders. Further, Catalyst is in the early stages of developing
CPP-115, another GABA aminotransferase inhibitor that could be more
potent than vigabatrin but may have reduced side effects (e.g.,
visual field defects, or VFDs) from those associated with
vigabatrin. Catalyst is planning to develop CPP-115 for several
indications, including epilepsy, drug addiction and neuropathic
pain. Catalyst believes that it controls all current intellectual
property for drugs that have a mechanism of action related to GABA
aminotransferase. For more information about the Company, go to
www.catalystpharma.com.
Source: Catalyst Pharmaceutical Partners, Inc.
CONTACT: Patrick J. McEnany, Catalyst Pharmaceutical, Chief
Executive
Officer, +1-305-529-2522, pmcenany@catalystpharma.com;
or Melody Carey, Rx
Communications Group, Co-President, +1-917-322-2571, mcarey@rxir.com
Web Site: http://www.catalystpharma.com/
Posted: June 2010
